BG
TNDM icon

Bellevue Group’s Tandem Diabetes Care TNDM Stock Holding History

Bellevue Group’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-782,456
Closed -$28.2M – 166
2024
Q4 		$28.2M Sell
782,456
-1,068,435
-58% -$36.1M 0.54% 45
2024
Q3 		$78.5M Buy
1,850,891
+307,624
+20% +$13M 1.27% 23
2024
Q2 		$62.2M Sell
1,543,267
-488,621
-24% -$20.4M 1.01% 25
2024
Q1 		$71.9M Buy
2,031,888
+39,571
+2% +$1.06M 1.1% 25
2023
Q4 		$58.9M Sell
1,992,317
-150,452
-7% -$3.12M 0.9% 33
2023
Q3 		$44.5M Buy
2,142,769
+49,835
+2% +$1.37M 0.72% 41
2023
Q2 		$51.4M Buy
2,092,934
+299,171
+17% +$9.62M 0.73% 43
2023
Q1 		$72.8M Buy
1,793,763
+2,313
+0.1% +$95.8K 1.06% 32
2022
Q4 		$80.5M Buy
1,791,450
+225,435
+14% +$10.2M 1.07% 26
2022
Q3 		$74.9M Buy
1,566,015
+250,142
+19% +$13.7M 1.08% 31
2022
Q2 		$77.9M Buy
1,315,873
+199,365
+18% +$16.4M 1.1% 28
2022
Q1 		$130M Buy
1,116,508
+167,251
+18% +$19.5M 1.51% 16
2021
Q4 		$143M Sell
949,257
-85,262
-8% -$11.5M 1.47% 17
2021
Q3 		$124M Buy
1,034,519
+14,151
+1% +$1.56M 1.25% 23
2021
Q2 		$99.4M Buy
1,020,368
+493,234
+94% +$44M 0.97% 30
2021
Q1 		$46.5M Buy
527,134
+141,950
+37% +$13.2M 0.49% 63
2020
Q4 		$36.9M Buy
385,184
+71,740
+23% +$7.39M 0.42% 69
2020
Q3 		$35.6M Buy
313,444
+81,605
+35% +$8.57M 0.49% 58
2020
Q2 		$22.9M Buy
231,839
+36,801
+19% +$2.94M 0.32% 73
2020
Q1 		$12.6M Sell
195,038
-5,109
-3% -$358K 0.24% 76
2019
Q4 		$11.9M Buy
200,147
+5,411
+3% +$334K 0.19% 83
2019
Q3 		$11.5M Buy
194,736
+26,889
+16% +$1.72M 0.21% 79
2019
Q2 		$10.8M Buy
167,847
+40,306
+32% +$2.6M 0.18% 81
2019
Q1 		$8.1M Buy
127,541
+28,288
+29% +$1.49M 0.45% 63
2018
Q4 		$3.77M Buy
99,253
+2,058
+2% +$72.7K 0.25% 79
2018
Q3 		$4.16M Sell
97,195
-16,811
-15% -$587K 0.26% 80
2018
Q2 		$2.51M Buy
+114,006
New +$1.4M 0.21% 79

Other funds holding TNDM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group's TNDM Position: Q1 2025 in Review

Bellevue Group sold out of Tandem Diabetes Care (TNDM) in Q1 2025, closing a stake of 782,456 shares — an estimated $28.2M sold.

Bellevue Group first reported a position in TNDM in Q2 2018 and held it in 27 quarters. The position peaked at $143M in Q4 2021. 275 funds tracked by Wall St. Rank hold TNDM as of Q1 2025.

  • Bellevue Group reported no remaining Tandem Diabetes Care position as of Q1 2025 after selling out during the quarter.
  • Bellevue Group sold 782,456 Tandem Diabetes Care shares in Q1 2025, an estimated $28.2M.
  • Bellevue Group first reported a position in Tandem Diabetes Care in Q2 2018 and held it in 27 quarters.
  • Bellevue Group's Tandem Diabetes Care position peaked at $143M in Q4 2021.
  • 275 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2025.

Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.